2160.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 08:15):

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally...

Stats
Dagens volum	765 500
Gjennomsnittsvolum	1.05M
Markedsverdi	124.25B
EPS	¥0 ( 2024-02-13 )
Neste inntjeningsdato	( ¥0 ) 2024-05-14
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	15.04
ATR14	¥1.910 (0.08%)

Volum Korrelasjon

Lang: -0.42 (neutral)

Kort: 0.45 (neutral)

Signal:(43.868) Neutral

GNI Group Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

GNI Group Ltd. Korrelasjon - Valuta/Råvare

-0.16
( neutral )

-0.03
( neutral )

0.86
( strong )

-0.58
( weak negative )

0.60
( weak )

-0.40
( neutral )

GNI Group Ltd. Økonomi

Annual	2023
Omsetning:	¥26.01B
Bruttogevinst:	¥22.43B (86.24 %)
EPS:	¥169.50

FY	2023
Omsetning:	¥26.01B
Bruttogevinst:	¥22.43B (86.24 %)
EPS:	¥169.50

FY	2022
Omsetning:	¥17.42B
Bruttogevinst:	¥14.74B (84.65 %)
EPS:	¥-18.29

FY	2021
Omsetning:	¥12.69B
Bruttogevinst:	¥11.09B (87.39 %)
EPS:	¥10.16

Financial Reports:

No articles found.

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.